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Abstract
Deep brain stimulation (DBS) is a functional neuromodulatory technique that 
involves the use of a neurostimulator to deliver electrical impulses to the brain. It pri-
marily alleviates the motor symptoms in neurodegenerative diseases; however, it has 
been found beneficial in a multitude of neurological and psychiatric diseases, such as 
dystonia, essential tremor, Tourette syndrome, intractable pain, epilepsy, treatment-
resistant depression, and obsessive-compulsive disorder. Nonmotor symptoms, 
such as neurobehavioral disorders, autonomic dysfunction, sleep dysfunction, and 
somatosensory dysfunction, play an important role in neurodegenerative diseases 
and have a significant impact on the quality of life. The effects of deep brain stimula-
tion on these symptoms are not yet apparent, although early results are promising 
and warrant future investigations. The main problem in interpretation is the lack of 
studies in this field, as most have methodological issues or small sample sizes, which 
limit the strength of the evidence. However, it is clear that DBS has a promising 
future in the treatment of neurodegenerative diseases in general and will have a vital 
role in personalized medicine as functional neuroimaging and our understanding of 
brain physiology improve.
Keywords: deep brain stimulation, nonmotor symptoms,  
neurodegenerative diseases, neuromodulation, neurostimulation
1. Introduction
Deep brain stimulation (DBS) is a functional neuromodulatory technique that 
involves the use of a neurostimulator to deliver electrical impulses to the brain [1]. 
It has been used for several decades, primarily in advanced Parkinson’s disease 
(PD), to alleviate the motor symptoms of the disease [2]. The exact mechanisms 
of therapeutic efficacy are not yet precisely defined; however, DBS is beneficial in 
a multitude of neurological and psychiatric diseases, such as dystonia, essential 
tremor, Tourette syndrome, intractable pain, epilepsy, treatment-resistant depres-
sion, and obsessive-compulsive disorder [3]. It is generally used to target specific 
locations in the brain that will be discussed later in the chapter. Despite this, the 
effects of DBS can be considered as systemic, as it influences neuronal pathways in 
both an upstream and a downstream manner. In that sense, it can affect a plethora 
of symptoms, including nonmotor symptoms in neurodegenerative diseases [4]. It is 
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becoming more apparent that neurostimulations will have an even more critical role 
in the future as our understanding of brain physiology and pathways improves with 
novel imaging techniques. This chapter includes the basics of how deep brain stimu-
lation works, what are the nonmotor symptoms in neurodegenerative diseases, and 
what is the current evidence on the effects of DBS on nonmotor symptoms.
2. Deep brain stimulation
2.1 How does deep brain stimulation work?
The system for DBS consists of three key components: an electrode that is placed 
in specific cerebral structures, an implantable pulse generator (IPG), and an exten-
sion that connects the two. Even though the exact mechanism is not yet known, the 
current hypothesis is that DBS works via excitation and inhibition of neurons and 
axons that are in proximity of the placed electrode [5]. The desired effect is achieved 
by changing the frequency of stimulations, as low-frequency stimulations most often 
excite nearby neurons [1], while high-frequency stimulations reduce local neuronal 
activity. Details of the implantation procedure are beyond the scope of this chapter, 
although it is useful to know that it is implanted stereotactically. In most cases, the 
stimulation is bilateral, although it is possible to stimulate unilaterally as well. The 
targets for stimulation are deep brain structures, as well as deep white matter tracts. 
A key benefit of DBS is the ability to adjust stimulations wirelessly via handheld 
devices to improve symptom relief and reduce possible side effects [5].
Currently used method for DBS function is based on an open-loop system, 
which enables trained physicians to adjust various settings depending on the 
patient’s condition [6]. This works adequately for most patients; however, changes 
in patient states bring challenges as modifying stimulations require a physician 
visit. A possible solution to this problem is the closed-loop or adaptive DBS that 
will enable real-time adjustment of the neurostimulations due to the continuous 
feedback signals. This will most likely be achieved with the help of various wearable 
sensors, neurochemical sensors, and electrophysiological recordings, which would 
all be interpreted with the Internet or mobile applications that will enable constant 
insight into the state of each patient [7]. Unfortunately, numerous challenges till 
the clinical application remain, but the prospects are bright, and hopefully such 
systems will be perfected in the near future.
The main and the most studied effect of DBS occurs via electrical potential gen-
erated by the neurostimulations. There was a prevailing thought that the effects of 
DBS are dominantly local in the areas that the electrodes were placed [8]. However, 
recent advances indicate that neuromodulation with DBS affects entire pathways, 
both afferently and efferently, and thus can influence more than just the stimulated 
structures [9]. Both animal and human studies in vivo show this, mainly through 
increased neurotransmitter release from axon functional magnetic resonance 
imaging (fMRI) studies [10]. In a practical sense, this means that targeting motor 
dysfunction, for example, in Parkinson’s disease, has an added effect of chang-
ing the function of other neuronal pathways and not only the motoric dopamine 
pathways that are primarily disrupted in the disease. Therefore, choosing the right 
target is essential for adequate treatment response.
2.2 Targets for stimulation
The two most common targets for DBS are the globus pallidus inter-
nus (GPi) and the subthalamic nucleus (STN), which are a part of the 
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cortico-basal-ganglia-thalamocortical circuit loop. They are most commonly used 
in Parkinson’s disease for control of dopaminergic symptoms such as tremor, rigid-
ity, and bradykinesia [5], although beneficial effects of GPi stimulation were found 
in dystonias as well [11]. Another possible target in PD is the ventral intermediate 
nucleus (VIM), an area of the thalamus, that if stimulated improves tremor-
dominant variants of the disease and can also be used in patients suffering from 
essential tremor [12]. Furthermore, stimulating the anterior nucleus can help in 
medically refractory epilepsy, while benefits of thalamic stimulation were also seen 
in Tourette’s syndrome, neuropathic pain, and traumatic brain injury as well.
Advancements in preclinical and neuroimaging research studies and neurosurgi-
cal experiences led to a discovery of several targets that could prove beneficial to 
numerous diseases. DBS in the ventral capsule, the ventral striatum, or nucleus 
accumbens (NA) has been shown to improve symptoms of obsessive-compulsive 
disorder [13], while NA stimulation has been shown to reduce the severity of 
obesity and anorexia [14]. Treating treatment-resistant depression is also possible 
with DBS; however it requires an individualized approach due to numerous pos-
sible targets [15]. Moreover, benefits of DBS are observed in dementia as well, with 
the possible targets being the fornix and the nucleus basalis of Meynert (NBM) in 
Alzheimer’s disease [16]. In general, the most reliable evidence for DBS use comes 
from movement disorders, while other indications still require randomized, well-
designed studies to prove efficacy. Different possible targets and adjustable nature 
of DBS put it at the forefront of personalized medicine in the future, especially as 
functional neuroimaging improves, as stimulations will be catered to each patient 
individually.
2.3 The mechanism of DBS
The neuromodulatory effects of DBS occur in various stages, while most of the 
focus in the early days of DBS was on the immediate effects. In time, it is becoming 
more apparent that short-term and long-term effects of DBS are just as significant, 
as those are opening new frontiers in therapy. All of the cells in the body function 
through changes in electric potential, but our neurons are special in the sense that 
they comprise a series of networks where this potential can be passed on to other 
neurons or cells [17]. This physiological basis creates the stage for neuromodulation 
with DBS, as different impulse settings create different effects on the cell bodies and 
axons of neurons. Even a single DBS pulse can influence neuronal activities for sev-
eral milliseconds, while an increased frequency can prevent the cells from resetting 
to their base values [18]. In neurons, these pulses dissociate cell bodies of neurons 
from their axons and essentially “hijack” the signaling in both afferent and efferent 
directions [19]. Generally, the pulses inhibit cell body activity while creating action 
potentials in the axons [20]. The pulses also act on astrocytes and microglia in the 
area of stimulation, causing a change in glial activity and complete changes in ion 
concentrations such as potassium and calcium, which in turn influences the changes 
in action potentials of neurons [21]. Immediate effects of DBS are a consequence of 
the function of individual neurons that are stimulated in the vicinity of the placed 
electrode and vary greatly depending on the selected target.
In the neurochemical sense, the milieu of brain tissue is significantly changing as 
several changes occur in the concentration of neurotransmitters and neurotrophic 
factors. The values of crucial neurotransmitters (dopamine, noradrenaline, sero-
tonin, and gamma-aminobutyric acid) are altered depending on the location of 
the modulation, which makes target selection key, as increasing serotonin [22] or 
noradrenaline by stimulating NA, for example, affects mood and can have an anti-
depressant effect [23]. However, even the presence of the electrode can significantly 
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impact the neurochemical properties surrounding it. It is a foreign object that 
necessitates reaction from microglia and astrocytes that create an immediate 
inflammation and edema that subsides over the long term with the creation of a 
fibrotic membrane by astrocytes [24, 25].
Most programs for DBS are intended for long-term function, and all these 
changes that happen immediately or short term after initiating the therapy have a 
profound effect on the structure and function over extended periods. The physi-
ological basis for this is a result of our brains’ adaptive capacity, which we call 
synaptic and neural plasticity [26]. Constant stimulation on the same areas and 
the changes mentioned above in neuronal activity and extracellular milieu lead 
to changes in synaptic structure and density, neurogenesis, and neuroprotection, 
which in turn change the properties of neural networks [27]. This is most likely 
mediated by neurotrophic factors, such as the brain-derived neurotrophic fac-
tor (BDNF), similarly as in the physiological central nervous system conditions 
[28]. The changes in neuroplasticity and neuronal organization lead to functional 
improvements of various symptoms over time; this is especially pronounced in 
alleviating neuropathic pain, axial symptoms, obsessive-compulsive symptomatol-
ogy, and several nonmotor symptoms as well [5].
Aside from the neurochemical changes, there are effects of DBS on brain oscil-
lations present in numerous neuropsychiatric diseases. Current data points out that 
synchronous brain activity can be amplified in Parkinson’s disease (beta oscillations 
in the basal ganglia [29]), Alzheimer’s disease (gamma oscillations in the hippo-
campus [30]), and treatment-resistant depression (gamma and theta oscillations in 
the subcallosal cingulate gyrus [31]). Early data indicates that DBS can affect these 
oscillations and provide a balance to brain activity, reducing the amplification that 
is pathologically found [30–32]. Further research is required to detect various oscil-
lation patterns in diseases to develop therapeutic goals for treatment, not only with 
DBS but with other neurostimulation techniques as well.
3. Nonmotor symptoms in neurodegenerative diseases
Nonmotor symptoms in neurodegenerative diseases are disturbances in neu-
robehavior, autonomic function, and sleep and sensory function that are not a 
consequence of motor symptoms [33]. Most of the studies are focused on nonmotor 
symptoms in Parkinson’s disease, but they can be present in most other central ner-
vous system disorders. The pathophysiology and incidence differ from one disease 
to another, although the spectrum of symptoms remains the same. In many cases, 
the first signs of neurodegeneration will be nonmotor disturbances as they often 
precede other symptoms [34]. It is important to point out that these symptoms are 
present as primary diseases as well, usually in the psychiatric spectrum of diseases. 
However, in the context of validated and approved DBS stimulation in the classical 
targets of stimulation, they can be considered as nonmotor symptoms in extrapyra-
midal diseases. It is clear that as the field matures, new nomenclature will be needed 
to accurately assess the effect of DBS on various neuropsychiatric symptoms, espe-
cially if those symptoms are primary targets (e.g., treatment-resistant depression or 
obsessive-compulsive disorder). We can divide the nonmotor symptoms into several 
key categories: neuropsychiatric symptoms, sleep disorders, autonomic symptoms, 
gastrointestinal symptoms, and sensory symptoms [33]. Nonmotor symptoms pres-
ent a vital field of study as they can have a significant impact on the quality of life 
and are often overlooked in clinical practice.
Neurobehavioral symptoms frequently present in neurodegenerative disorders 
are excessive fatigue, depression, anxiety, apathy, and cognitive dysfunction. 
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Depression and anxiety both commonly occur at the same time in patients and 
often precede diagnosis with mild symptoms at the beginning, although more 
severe forms occur as the disease progresses [35]. On the other hand, apathy can 
be present as a separate symptom, mainly if there is a prominent degeneration 
of dopamine pathways in the limbic system [36]. Finally, cognitive dysfunction 
is considered as an inevitable consequence of long-term neurodegeneration. The 
extent of cognitive difficulties varies from mild to severe depending on the disease, 
with different cognitive domains affected as well [37].
Sleep dysfunction and sleep-related problems are common nonmotor symptoms 
in neurodegenerative diseases. The pathophysiological basis is likely the variation 
in physiological dopamine function, as changes in dopamine are known to impact 
wakefulness [38]. The physiological importance of sleep comes from enabling the 
regeneration of brain tissue and reestablishing homeostatic conditions. Therefore, 
sleep disorders can increase the severity of disease progression as a vicious circle 
forms that disables proper neural regeneration [39]. Sleep-onset insomnia is a 
frequent occurrence in neurodegenerative diseases, as the progression of the disease 
and chronic loss of neuronal function lead to neurotransmitter disbalance that in 
turn causes a sleep-wake disruption. This presents as a dysfunction of the circadian 
rhythm in Alzheimer’s disease and Huntington’s disease, while in Parkinson’s dis-
ease the difficulties are mostly sleeping through the night and initiation of rapid eye 
movement phase during sleep [40]. Sleep quality can also be affected, as difficulties 
in nighttime mobility and excessive fragmentation of sleep are common, as well as 
problems in rapid eye movement (REM) phases of sleep [41]. Furthermore, dif-
ficulties with restless legs syndrome (RLS) and involuntary limb movements create 
sleep difficulties, although these symptoms are more frequently found in diseases 
that feature dopamine dysfunction and generally have a response to dopamine 
therapy [42].
Autonomic dysfunction develops as a consequence of progressive degeneration 
in neural pathways, mostly in diseases characterized by the accumulation of Lewy 
bodies or α-synuclein, and is much less pronounced in diseases such as Alzheimer’s 
or frontotemporal lobar degeneration [43]. Three main symptoms of autonomic 
dysfunction are issues with bladder control, nocturia, and sexual dysfunction, all of 
which are linked to the dysfunction in the dopamine pathways and can somewhat 
improve with dopaminergic therapy [44]. Moreover, gastrointestinal symptoms 
fall in this category as well and are an interesting subset of symptoms as the dys-
function, which often presents as constipation or anorectal dysfunction, could 
be a consequence of both central and enteric nervous system degeneration [45]. 
Interestingly, these symptoms can be present in prodromal stages of many neurode-
generative diseases, which have made the gut-brain axis an attractive research target 
in recent times [46].
Finally, sensory symptoms have a significant role in the clinical course of neu-
rodegenerative diseases, especially in the prodromal stages. Hyposmia, a reduced 
capacity for the sense of smell, is often seen in the early stages of Parkinson’s and 
Alzheimer’s disease [47, 48]. Recent neuroimaging studies reveal a decreased 
volume in the olfactory regions of the brain, while neuropathological studies found 
a high accumulation of α-synuclein, αβ amyloid, and Tau proteins in the olfactory 
bulb during the early stages of neurodegenerative diseases [47, 48]. Something 
similar can be seen in the optical pathways as well, as there is an increase of visual 
hallucinations, reduced color recognition, visual acuity problems, and double 
vision as neurodegeneration progresses [49]. Pain syndromes are frequent as well 
and are more likely of neuropathic origin. Unfortunately, the mechanisms for pain 
in neurodegeneration are varied, and managing pain requires an individualized 
approach, as specific types of pain require different medications. High prevalence 
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of pain impacts the quality of life, as do all nonmotor symptoms in general, which 
makes proper measurement a necessity in the current clinical evaluation of neuro-
degenerative diseases.
3.1 How do we measure nonmotor symptoms?
Comprehensive measurements of all the symptoms mentioned present a chal-
lenge in everyday clinical practice. Naturally, objectifying the symptoms is crucial 
not only in the initial evaluation but also in the evaluation of the therapeutic effects 
as well. There is a wide variety of instruments available for a detailed assessment 
of each symptom, but this has proven to be inadequate in everyday use [50]. Best 
suited scales for rapid and accurate identification of nonmotor symptoms are 
multidomain instruments that cover most of the nonmotor symptomatology. Two 
scales were developed for use in Parkinson’s disease; however, they are suitable for 
use in other neurodegenerative diseases as a quick screening of the prevalence of 
nonmotor symptoms.
First is the nonmotor symptom questionnaire (NMSQuest), a scale developed 
to provide a useful screening tool, as it contains 30 items that have yes and no 
questions covering various domains of nonmotor symptoms [51]. It is designed 
to be completed by patients themselves, and there is no grading of the severity of 
symptoms, just whether they exist or not. Nonetheless, it has proven to be an effec-
tive screening tool in further validation studies that can afterward lead to a more 
focused examination of reported symptoms [52]. On the other hand, the nonmotor 
symptom scale (NMSS) is developed to be rated by clinicians, and it incorporates 
the severity and impact of the symptoms on the daily life of the patients [53]. 
Similar to the NMSQuest, it has 30 items, spread across 9 domains, but the overlap 
is in 23 of the 30 items; therefore using both of them has clinical sense. It is crucial 
to point out that these scales have inevitable shortcomings as more nonmotor 
symptoms come into focus over time. Therefore, a modified NMSS is currently in 
active development that should improve its use in all neurodegenerative diseases. 
Furthermore, it is required to use the scales focused on each domain to precisely 
measure the severity of each symptom on its own, as only focused scales go into 
enough details to have a complete overview of the effect that each symptom has on 
the quality of life. In any case, as the focus of symptomatology studies turn toward 
nonmotor symptoms, it is to be expected that more comprehensive scales will be 
developed that are adequate for use in clinical and clinical trial settings.
4. Effects of DBS on nonmotor symptoms
The focus of clinical practice and research in DBS is on the effects it has for 
motor symptoms in advanced Parkinson’s disease. As previously said, the nonmotor 
symptoms in neurodegenerative diseases are only recently coming into focus, as 
is the effect of DBS on them. Most robust studies come from the research done in 
Parkinson’s disease and from patients whose targets for neuromodulation are STN 
and GPi; however, research from other diseases and stimulation targets will also be 
assessed in the coming paragraphs [54].
4.1 Neurobehavioral symptoms
Effects of DBS on neurobehavioral outcomes are a complex subject as there are 
possible advantages and disadvantages, depending on the initial patient selection 
and the deep brain target of neuromodulation. Cognitive dysfunction, as a frequent 
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symptom in most neurodegenerative diseases, can have varying severity depend-
ing on the disease and between each patient individually [55]. In classical DBS 
targets, the STN and GPi, there are mixed results regarding the effect on cognition. 
Generally, stimulation of these areas will not improve cognitive function, and there 
is even a mild risk of cognitive decline, which has been found minor in more exten-
sive trials and not clinically relevant [4]. There is a caveat to this, as DBS in patients 
with pronounced cognitive dysfunction tends to increase the severity of symptoms 
more than in those who do not have significant cognitive impairment [56]. The 
same can be observed in patients who had problems with depression or anxiety 
in the past before being diagnosed with a neurodegenerative condition [57]. STN 
stimulations, in particular, led to an increase in apathy and hallucinations, while 
there was a minor improvement in impulsive behavior (impulse buying, gambling, 
excessive sexual behavior) compared to the control groups [58–60]. Benefits of DBS 
were found in symptoms of depression as well but mostly in milder cases without 
pronounced symptoms [61].
On the other hand, phase I clinical studies in Alzheimer’s disease with DBS target-
ing the fornix [62] or the NBM [63] show encouraging results on cognitive impair-
ment in the early stages of the disease while being safe and well tolerated. There is 
currently a lack of studies in this field, but more are being conducted at the time of 
writing. Furthermore, early research shows that patients who suffer from depres-
sion could benefit from DBS, especially severe types that are resistant to therapy. 
Similar to Alzheimer’s disease, there are promising early results, but proper targets 
and correct settings for stimulations are not yet clear, and larger, controlled studies 
are needed [15]. To summarize, the effects of DBS on neurobehavioral symptoms are 
significantly impacted by the target locations for stimulation, as both beneficial and 
harmful effects are present. Therefore, appropriate patient selection is critical, as the 
impact it can have on the quality of life depends much on an individual basis.
4.2 Autonomic dysfunction
Dysfunctions in the autonomous nervous system are the more frequent nonmo-
tor symptoms in neurodegenerative diseases. Generally, there is a lack of extensive 
studies featuring a high number of patients, and studying the effects of DBS 
on autonomic dysfunction is usually not the main focus. Dysautonomia is more 
frequently found in movement disorders than other diseases in the neurodegenera-
tion disease spectrum [43]. Early studies that focus on STN and GPi stimulation 
reveal that DBS has a beneficial effect on urinary symptoms, especially in reducing 
nocturia, frequency, and urgency [64]. The most likely mechanism, revealed by 
urodynamic evaluation, is through increased bladder capacity and reflex volume, 
and the effect seems to persist over time after initial surgery [65, 66]. Similarly, 
neuromodulation with DBS appears to be beneficial in gastrointestinal function 
as well, especially in the early phases after surgery. Significant improvement was 
found in constipation, salivation, and gastric emptying, as the contractions of the 
whole gastrointestinal tract improved [67–69]. However, studies show that there is 
no effect on dysphagia, possibly due to a different mechanism that causes it com-
pared to problems with emptying the gastrointestinal tract [70]. Sexual dysfunction 
is not significantly impacted by DBS, with most patients reporting a slight improve-
ment, especially in younger patients [71].
4.3 Sleep
Sleep disorders have a significant impact on the quality of life, as they 
lead to fatigue and daytime sleepiness. Sleep quality is often disrupted in 
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neurodegenerative diseases and has been a subject of study after initiating 
DBS. Polysomnographic studies show that DBS in STN leads to an objective 
improvement sleep quality [72], which is seen in subjective-based studies as well 
[73, 74]. Improvement in sleep and pain was also observed in dystonia patients who 
were treated with STN DBS [75]. Interestingly, daytime sleepiness does not seem to 
be affected by DBS [76]. A possible reason for this could be a lacking effect on REM 
sleep, as DBS patients have an increased risk of developing REM sleep behavioral 
disorder in the case of STN stimulations [77]. The effect on restless legs syndrome 
appears to be positive in moderate to severe cases, but new cases of the syndrome 
can appear after initiating DBS [78, 79]. Overall, it seems that constant stimulations 
improve sleep quality over the long term by influencing nighttime mobility and 
sleep maintenance.
4.4 Sensory functions
Somatosensory dysfunction is often reported in neurodegenerative diseases and 
presents a significant burden in everyday life of the patients. Problems with the 
sense of smell and taste arise in the early phases of neurodegeneration. Subjective 
improvement in both smell and taste was reported in a recent prospective study 
[64]. It appears that the improvement in smell stems from improved odor informa-
tion processing, as only odor discrimination and identification were improved, 
while the detection was not affected by DBS [80, 81]. There are improvements in 
visual function as well, mostly due to the effect on ocular smooth motor function 
and improving problems with saccade movement [82]; however, the amount of 
evidence in this field is severely limited and still inconclusive.
Fortunately, the DBS effects on pain are more apparent. Most studies suggest a 
beneficial effect of DBS on pain [83], especially in patients who suffer from pain in 
off periods [84]. There are varied types of pain that can be present in patients, but 
it appears that STN DBS has a substantial effect in curbing dystonic and musculo-
skeletal pain, while central and neuropathic pain are less affected [85]. However, 
severe neuropathic pain can be treated with DBS if the target for stimulations is the 
periaqueductal gray matter, possibility due to an increased release of endogenous 
opioids [86, 87]. There are promising results in chronic pain as well, with the 
anterior cingulate cortex showing potential, though it is too early to tell due to a 
lack of studies in this field [88]. This finding underlines the importance of selecting 
the right target for neuromodulation depending on the wanted results, which holds 
promise for the future of DBS.
5. Conclusion
Nonmotor symptoms represent a challenge in the treatment of neurodegenera-
tive diseases and have a significant influence on the quality of life. DBS shows 
promise in alleviating these symptoms, depending significantly on the target of 
stimulation. The main problem is the lack of studies in this field, as most have 
methodological issues or small sample sizes, which limit the strength of the evi-
dence. Likewise, only a handful of studies have nonmotor symptoms and primary 
end points. The number of approved indications for DBS is still small and mostly 
focused on extrapyramidal symptoms, and therefore, most studies are focused on 
the effects of DBS in STN or GPi. However, it is clear that DBS has a promising 
future in the treatment of neurodegenerative diseases in general and will have 
an important role in personalized medicine as functional neuroimaging and our 
understanding of brain physiology improves.
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Appendices and nomenclature
DBS deep brain stimulation
PD Parkinson’s disease
IPG implantable pulse generator
fMRI functional magnetic resonance imaging
GPi globus pallidus internus
STN subthalamic nucleus
VIM ventral intermediate nucleus
NA nucleus accumbens
NBM nucleus basalis of Meynert
BDNF brain-derived neurotrophic factor
REM rapid eye movement
RLS restless legs syndrome
NMSQuest nonmotor symptom questionnaire
NMSS nonmotor symptom scale
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